세계의 신경 대사장애 시장 : 시장 규모 분석(유형별, 진단 방법별, 치료 접근별, 최종사용자별, 지역별)과 예측(2022-2032년)

The Global Neurometabolic Disorders Market is valued approximately at USD 7.77 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 6.02% over the forecast period 2024-2032. Neurometabolic disorders, a diverse group of rare, genetically driven conditions affecting the brain's metabolic function, have emerged as a critical frontier in modern medical research and care delivery. These conditions, often manifesting early in life, are driven by defects in metabolic pathways involving amino acids, fatty acids, and mitochondrial functions. What sets this market apart is the urgency and complexity of care required, which has catalyzed innovation across diagnostic technologies and therapeutic modalities. A growing global awareness, increased newborn screening programs, and expanding access to genomic medicine are reshaping patient journeys from delayed diagnosis to early intervention-unlocking the potential for improved long-term outcomes.

As the landscape of rare diseases evolves, the neurometabolic disorders market has found momentum propelled by surging investments in genomic sequencing, molecular diagnostics, and innovative therapies. Diagnostic methods such as neuroimaging, biochemical testing, and next-generation sequencing are now playing pivotal roles in enabling clinicians to pinpoint rare inborn errors of metabolism with enhanced accuracy. Moreover, pharmacological advancements such as gene therapy, enzyme replacement, and dietary interventions are not only addressing symptoms but are now beginning to modify disease course in select conditions. Governments and private players alike are funding research pipelines and launching patient support initiatives, which are contributing to increased therapeutic approvals and robust product pipelines.

However, despite remarkable progress, the market continues to be hindered by several structural challenges. A significant barrier remains the high cost of advanced diagnostics and specialized therapies-frequently unaffordable or inaccessible in low- and middle-income regions. Additionally, the rarity and variability of neurometabolic disorders often result in limited clinical data, hindering large-scale trials and slowing regulatory approval. The intricacies of managing these disorders also demand multidisciplinary expertise, yet such teams are not universally available. These limitations underscore the need for innovative business models, cross-border collaborations, and real-world evidence frameworks to accelerate progress and drive equitable care access.

Yet, in the face of these hurdles, several dynamic forces continue to expand the opportunity space. The emergence of precision medicine and gene editing tools such as CRISPR has opened the door to potentially curative therapies, especially for monogenic neurometabolic conditions. Simultaneously, increasing academic-industry partnerships and digital health integration are fostering decentralized diagnostic platforms and home-based treatment options-particularly important for pediatric patients with chronic care needs. Pharmaceutical companies are increasingly prioritizing rare disease portfolios, encouraged by orphan drug designations and regulatory incentives from the U.S. FDA and European Medicines Agency, thereby contributing to heightened R&D activity across this niche but impactful market.

From a regional standpoint, North America currently commands a leading share of the neurometabolic disorders market, supported by favorable reimbursement policies, sophisticated healthcare infrastructure, and pioneering research hubs in the United States and Canada. Europe follows closely, bolstered by expansive newborn screening programs, rare disease registries, and public health funding. Meanwhile, Asia Pacific is expected to register the fastest growth over the forecast period, with rising healthcare expenditure, rapid adoption of genetic diagnostics, and a growing footprint of multinational pharmaceutical players in countries like India, China, and Japan. Latin America and the Middle East & Africa, although currently underpenetrated, are progressively integrating rare disease management into their national health strategies, signaling a gradual but important shift toward inclusive access.

Major market player included in this report are:

• Sanofi S.A.
• BioMarin Pharmaceutical Inc.
• Takeda Pharmaceutical Company Limited
• Ultragenyx Pharmaceutical Inc.
• AbbVie Inc.
• Genzyme Corporation
• Amicus Therapeutics, Inc.
• Horizon Therapeutics plc
• Aeglea BioTherapeutics, Inc.
• Retrophin, Inc.
• BridgeBio Pharma, Inc.
• Orchard Therapeutics
• Alexion Pharmaceuticals, Inc.
• Stealth BioTherapeutics Corp.
• Acer Therapeutics Inc.

The detailed segments and sub-segment of the market are explained below:

By Type

• Amino Acid Disorders
• Organic Acidemias
• Fatty Acid Oxidation Disorders
• Mitochondrial Disorders
• Neurodegenerative Disorders

By Diagnosis Method

• Neuroimaging
• Biochemical Testing
• Genetic Testing
• Electroencephalography
• Lumbar Puncture

By Therapeutic Approaches

• Dietary Management
• Gene Therapy
• Enzyme Replacement Therapy
• Supportive Therapies
• Pharmacological Treatment

By End User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Homecare Settings
• Pharmaceutical Companies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Neurometabolic Disorders Market Executive Summary

• 1.1. Global Neurometabolic Disorders Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Diagnosis Method
  • 1.3.3. By Therapeutic Approaches
  • 1.3.4. By End User
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Neurometabolic Disorders Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Payer & Patient Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Disease Prevalence & Awareness
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Reimbursement Landscape
    • 2.3.4.4. Patient Access & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Neurometabolic Disorders Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Expansion of Newborn Screening & Genomic Medicine
  • 3.1.2. Surging Investments in Molecular Diagnostics & Therapies
  • 3.1.3. Orphan Drug Incentives & Public-Private Funding
• 3.2. Market Challenges
  • 3.2.1. High Cost & Limited Access to Advanced Care
  • 3.2.2. Rarity & Limited Clinical Data
  • 3.2.3. Demand for Multidisciplinary Expertise
• 3.3. Market Opportunities
  • 3.3.1. Gene Therapy & CRISPR-Based Precision Medicine
  • 3.3.2. Digital Health Integration & Home-Based Care
  • 3.3.3. Rapid Growth in Asia Pacific Emerging Markets

Chapter 4. Global Neurometabolic Disorders Market Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's Five Forces
  • 4.1.7. Porter's Five Forces Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economic
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Neurometabolic Disorders Market Size & Forecasts by Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Market: Amino Acid Disorders Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 5.3. Global Market: Organic Acidemias Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 5.4. Global Market: Fatty Acid Oxidation Disorders Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 5.5. Global Market: Mitochondrial Disorders Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 5.6. Global Market: Neurodegenerative Disorders Revenue Trend Analysis, 2022 & 2032 (USD Million)

Chapter 6. Global Neurometabolic Disorders Market Size & Forecasts by Diagnosis Method 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Market: Neuroimaging Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 6.3. Global Market: Biochemical Testing Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 6.4. Global Market: Genetic Testing Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 6.5. Global Market: Electroencephalography Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 6.6. Global Market: Lumbar Puncture Revenue Trend Analysis, 2022 & 2032 (USD Million)

Chapter 7. Global Neurometabolic Disorders Market Size & Forecasts by Therapeutic Approaches 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Market: Dietary Management Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 7.3. Global Market: Gene Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 7.4. Global Market: Enzyme Replacement Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 7.5. Global Market: Supportive Therapies Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 7.6. Global Market: Pharmacological Treatment Revenue Trend Analysis, 2022 & 2032 (USD Million)

Chapter 8. Global Neurometabolic Disorders Market Size & Forecasts by End User 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Market: Hospitals Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 8.3. Global Market: Diagnostic Laboratories Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 8.4. Global Market: Research Institutes Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 8.5. Global Market: Homecare Settings Revenue Trend Analysis, 2022 & 2032 (USD Million)
• 8.6. Global Market: Pharmaceutical Companies Revenue Trend Analysis, 2022 & 2032 (USD Million)

Chapter 9. Global Neurometabolic Disorders Market Size & Forecasts by Region 2022-2032

• 9.1. North America Market
  • 9.1.1. U.S. Market
    • 9.1.1.1. By Type breakdown size & forecasts, 2022-2032
    • 9.1.1.2. By End User breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Market
• 9.2. Europe Market
  • 9.2.1. U.K. Market
  • 9.2.2. Germany Market
  • 9.2.3. France Market
  • 9.2.4. Spain Market
  • 9.2.5. Italy Market
  • 9.2.6. Rest of Europe Market
• 9.3. Asia Pacific Market
  • 9.3.1. China Market
  • 9.3.2. India Market
  • 9.3.3. Japan Market
  • 9.3.4. Australia Market
  • 9.3.5. South Korea Market
  • 9.3.6. Rest of Asia Pacific Market
• 9.4. Latin America Market
  • 9.4.1. Brazil Market
  • 9.4.2. Mexico Market
  • 9.4.3. Rest of Latin America Market
• 9.5. Middle East & Africa Market
  • 9.5.1. Saudi Arabia Market
  • 9.5.2. South Africa Market
  • 9.5.3. Rest of Middle East & Africa Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
  • 10.1.1. Sanofi S.A.
  • 10.1.2. BioMarin Pharmaceutical Inc.
  • 10.1.3. Takeda Pharmaceutical Company Limited
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. Sanofi S.A.
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. BioMarin Pharmaceutical Inc.
  • 10.3.3. Takeda Pharmaceutical Company Limited
  • 10.3.4. Ultragenyx Pharmaceutical Inc.
  • 10.3.5. AbbVie Inc.
  • 10.3.6. Genzyme Corporation
  • 10.3.7. Amicus Therapeutics, Inc.
  • 10.3.8. Horizon Therapeutics plc
  • 10.3.9. Aeglea BioTherapeutics, Inc.
  • 10.3.10. Retrophin, Inc.
  • 10.3.11. BridgeBio Pharma, Inc.
  • 10.3.12. Orchard Therapeutics
  • 10.3.13. Alexion Pharmaceuticals, Inc.
  • 10.3.14. Stealth BioTherapeutics Corp.
  • 10.3.15. Acer Therapeutics Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes